Takeda exits cell therapy research
Takeda will seek an external partner to leverage its cell therapy platform technologies
Takeda will seek an external partner to leverage its cell therapy platform technologies
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Facility designed to advance the next generation of imaging systems
Inclacumab was generally well tolerated in THRIVE-131
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated